Navigation Links
Decline in Paternity Rates Following Treatment for Testicular Cancer

A recent study published in the November issue of the Journal of the National Cancer Institute, shows that paternity rates of testicular cancer patients declined after treatment, and patients treated with the higher chemotherapy dose had the lowest chance of becoming fathers. //

Germ-cell testicular cancer is the most common cancer among 20-40 year old men. Many testicular cancer patients are diagnosed at an age at which they are starting a family, and the ability to father children in the future is an important issue for approximately 60% of newly diagnosed patients.

Subfertility or infertility can be associated with the disease itself or with its treatment. Approximately half of all testicular cancer patients have defective spermatogenesis at diagnosis, even before orchiectomy.

Researchers from Norway assessed post-treatment paternity among long-term survivors of testicular cancer whose treatment had followed a modern management approach. A total of 1814 men who had been treated for unilateral testicular cancer in Norway during 1980 through 1994 were invited to participate in a national multi-center follow-up survey in 1998 through 2002.

The participants were allocated to five groups according to the treatment received after orchiectomy, including treatment at relapse (surveillance, retroperitoneal lymph node dissection, radiotherapy, low-dose chemotherapy, and high-dose chemotherapy).

Results obtained depicted that a total of 1433 men were assessable, of whom 827 were fathers at diagnosis. 554 men had attempted post-treatment conception, among whom the overall 15-year actuarial post-treatment paternity rate was 71% without the use of cryopreserved semen. This rate ranged from 48% in the high-dose chemotherapy group to 92% in the surveillance group.

Assisted reproductive technologies were used by 22% of the couples who attempted conception after treatment. Dry ejaculation, treatment group, pretreatment fa therhood, and marital status were statistically significant independent predictors for post-treatment fatherhood, with dry ejaculation as the most important negative factor.

The authors conclude that post-treatment paternity rates in all treatment groups were lower than those in the surveillance group. Patients treated with the higher chemotherapy dose (i.e., more than 850 mg of cisplatin) had the lowest chance of becoming fathers. However, even among these most intensively treated men, almost half were able to father children.

Although the overall paternity rate after treatment for testicular cancer was high, the ability to conceive and the time to conception reflected the intensity of treatment. The authors hope that these data may help inform patients about their future ability to father biological children
'"/>




Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Anemia may Lead to Physical Decline
3. Exercise Can Decrease Mental Decline
4. Folic Acid Retards Mental Decline In Middle Aged Subjects
5. Breastfeeding Decline In Middle East Worries UN
6. Preventing Age-Related Mental Decline By Consuming Vitamin B
7. Drug Use On The Decline Among US Youth
8. Delhi Sees Sharp Decline In Chicken Prices
9. Global Seagrass Decline Affects Shallow-water Ecosystems
10. Decline of Suicide Rates to a Record Low, Holds Promise
11. Contraceptive Use on the Decline among the Poor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... , ... May 27, 2016 , ... ... to help educate the many who are unaware of the plight of aphasia. ... will run within the “Stroke Awareness” campaign. , The link between stroke and ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... students studying complementary medicine. Allison Outerbridge is this year’s Life University ... May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: